BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® for Children With Achondroplasia
BioMarin Announces New Three-Year VOXZOGO® Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® in Children with Hypochondroplasia
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
Edgewater Wireless Reports Fiscal 2026 Year-End Results and Highlights Growing Semiconductor Execution and Industry Validation
Silver Hammer and Stroud Resources Announce Updated Mineral Resource Estimate for the Santo Domingo Silver-Gold Project, Mexico
